Every 8-K that Encompass Health Corp (EHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EHC filings page.
Encompass Health Corporation completed a private issuance and sale of $100 million aggregate principal amount of 5.875% Senior Notes due 2034, guaranteed by certain subsidiaries. The notes were sold at 98.75% of principal, generating approximately $96.9 million in net proceeds after initial purchasers’ discounts and estimated expenses.
The company used the net proceeds, together with cash on hand, to repay a portion of the outstanding amounts under its revolving credit facility. These new notes are an additional issuance under the existing May 29, 2026 indenture, where $500,000,000 of identical 5.875% Senior Notes due 2034 are already outstanding. The new and existing notes form a single class under the indenture and rank pari passu.
Encompass Health Corporation reported higher results for Q2 2026, with net operating revenues of $1,597.4 million, up 9.6% from Q2 2025. Diluted earnings per share from continuing operations were $1.55 compared with $1.40, and Adjusted EBITDA rose 9.2% to $348.0 million. Discharges increased 5.6% to 68,895, driven by 2.8% same‑store discharge growth and a 3.9% rise in net patient revenue per discharge to $22,521.
For the first six months of 2026, net operating revenues reached $3,184.0 million and net income attributable to Encompass Health was $348.4 million, with diluted EPS from continuing operations of $3.32. Management raised full‑year 2026 guidance, projecting net operating revenue of $6,410 to $6,490 million, Adjusted EBITDA of $1,365 to $1,395 million, and adjusted earnings per share of $6.02 to $6.25. Results and outlook are presented using several non‑GAAP measures such as Adjusted EBITDA, adjusted EPS, leverage ratio, and adjusted free cash flow, each reconciled to GAAP metrics.
Liquidity included net cash provided by operating activities of $282.6 million in Q2 and $595.7 million year‑to‑date, while adjusted free cash flow totaled $177.0 million for Q2. The board increased aggregate common stock repurchase authorization to $1 billion; the company had repurchased $145.8 million of common stock year to date and reported cash and cash equivalents of $107.7 million at June 30, 2026.
Encompass Health Corporation issued and sold $500 million of 5.875% Senior Notes due 2034 in a private offering, receiving about $491.2 million in net proceeds. The company plans to use this cash, along with existing cash on hand, to redeem at par $400 million of its 4.500% senior notes due 2028, repay $100 million outstanding under its revolving credit facility, and cover related fees and expenses.
The new notes are senior unsecured obligations, guaranteed on a senior unsecured basis by certain subsidiaries, and pay interest semiannually each June 1 and December 1 until maturity on June 1, 2034. The indenture includes optional redemption features, a change-of-control repurchase right at 101% of principal, and customary covenants and events of default, including cross-default and judgment thresholds of $100 million.
Encompass Health Corporation has agreed to issue $500 million in aggregate principal amount of 5.875% senior notes due 2034 in a private offering, with closing expected on or about May 29, 2026, subject to the purchase agreement terms. The notes will be guaranteed on a senior unsecured basis by certain subsidiaries and sold to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.
The company currently intends to use the net proceeds, together with cash on hand, to redeem at par $400 million of its outstanding 4.500% Senior Notes due 2028, repay $100 million under its senior secured revolving credit facility, and pay related fees and expenses. Encompass Health describes itself as the largest owner and operator of inpatient rehabilitation hospitals in the United States, with 175 hospitals in 39 states and Puerto Rico.
Encompass Health Corporation reported the results of its Annual Meeting held on May 7, 2026. Stockholders voted on electing ten directors, ratifying PricewaterhouseCoopers LLP as independent auditor, and approving the compensation of named executive officers.
There were 99,565,304 common shares outstanding as of the record date, with each share entitled to one vote. Votes representing 92.5% of the combined voting power were present by proxy. All ten director nominees received strong support, with votes for each nominee ranging from about 83.9 million to 85.9 million.
Ratification of PricewaterhouseCoopers LLP passed with 88,444,873 votes for, 3,608,490 against, and 68,452 abstentions. The advisory vote on executive compensation (say-on-pay) passed with 83,410,829 votes for, 3,006,776 against, and 102,636 abstentions, along with 5,601,574 broker non-votes on both the director and compensation proposals.
Encompass Health Corporation reported strong first-quarter 2026 results and raised its full-year outlook. Net operating revenue grew 9.0% to $1,586.6 million, driven by 4.3% higher discharges and a 3.7% increase in net patient revenue per discharge to $22,633.
Adjusted EBITDA rose 11.2% to $348.8 million, while diluted earnings per share from continuing operations increased to $1.77, with adjusted earnings per share up 16.8% to $1.60. Adjusted free cash flow was $193.8 million, down from $222.4 million a year earlier, reflecting higher maintenance capital spending and distributions to noncontrolling interests.
The company continued to expand capacity, opening a new 49-bed hospital in Irmo, South Carolina and adding 44 beds at existing facilities. It amended and restated its credit agreement, extending maturity to March 2031, and reported net leverage of 1.9x. Encompass Health repurchased 707,965 shares for $71.6 million and paid a quarterly dividend of $0.19 per share.
For full-year 2026, management modestly increased guidance, now expecting net operating revenue of $6,375 million to $6,470 million, Adjusted EBITDA of $1,350 million to $1,380 million, and adjusted earnings per share from continuing operations of $5.89 to $6.11.
Encompass Health Corporation entered a new credit agreement on March 9, 2026, establishing a $1 billion revolving credit facility with a maturity of March 9, 2031. The facility includes a $260 million letter of credit subfacility and a swingline loan sublimit increased to $40 million.
The company used $250.0 million of borrowings and $53.6 million of letters of credit under the new facility to repay and retire all remaining obligations under its prior 2022 credit agreement, which was terminated along with its related collateral and guarantee agreement.
The new agreement keeps terms substantially similar but lowers the undrawn commitment fee by 5 basis points, eliminates a 0.10% Term SOFR interest adjustment, relaxes certain investment, debt, lien, and restricted payment limits, and adds an accordion feature allowing additional term loans or increased revolving commitments, subject to leverage and coverage covenants.
Encompass Health Corporation filed an amended report to update a recent Board change. The Board had unanimously approved the appointment of Cain A. Hayes as a director on January 30, 2026. The amendment notes that on February 19, 2026, the Board appointed Mr. Hayes to the Compensation and Human Capital Committee and the Compliance and Quality of Care Committee. This filing supplements an earlier report originally filed on February 2, 2026, by providing these committee assignments for the new director.
Encompass Health Corporation filed a Form 8‑K to furnish its financial results for the three months and year ended December 31, 2025, as disclosed in a press release (Exhibit 99.1) and supplemental earnings materials (Exhibit 99.2).
The company explains its use of same‑store comparisons, which include hospitals open in both periods and incorporate market consolidations and capacity expansions where isolating incremental impact is difficult. It also highlights several non‑GAAP measures: adjusted earnings per share, Adjusted EBITDA, leverage ratio, and adjusted free cash flow.
Encompass Health describes how Adjusted EBITDA and its leverage ratio are central to covenants in its credit agreement, affecting the ability to incur debt, pay dividends, and make certain investments. The filing also outlines the company’s definition of adjusted free cash flow and includes extensive cautionary language about forward‑looking statements tied to its strategy, growth targets, capital plans, and financial outlook.
Encompass Health Corporation reported that its Board of Directors elected Cain A. Hayes as a director on January 30, 2026, following a recommendation from its Nominating/Corporate Governance Committee. The Board has determined that Mr. Hayes is independent under New York Stock Exchange listing standards and the company’s Corporate Governance Guidelines.
Mr. Hayes will receive compensation consistent with the company’s standard practices for nonemployee directors, as described in its April 1, 2025 proxy statement. The company stated there are no arrangements or understandings with other persons related to his selection and no related party transactions involving him that require disclosure. A press release dated February 2, 2026, announcing his election, is included as an exhibit.
Encompass Health Corporation is reaffirming its full-year 2025 outlook as it meets with investors and analysts in early December. The company continues to project net operating revenue between $5,905 million and $5,955 million, reflecting its expectations for demand across its rehabilitation hospitals.
For profitability, Encompass Health maintains guidance for 2025 Adjusted EBITDA in a range of $1,235 million to $1,255 million, and Adjusted earnings per share from continuing operations attributable to Encompass Health between $5.22 and $5.37. Management emphasizes that most guidance metrics are non‑GAAP and excludes items such as legal settlements, certain professional fees, hedging gains or losses, debt extinguishment costs, restructuring items, and specific tax adjustments. The company also estimates 2025 interest expense and amortization of debt discounts and fees of about $125 million and amortization of debt‑related items of about $10 million.
Encompass Health (EHC) furnished its third‑quarter 2025 results via a press release and supplemental materials attached as Exhibits 99.1 and 99.2 to an Item 2.02/7.01 Form 8‑K. The materials include definitions and reconciliations for non‑GAAP measures such as adjusted earnings per share, Adjusted EBITDA, leverage ratio, and adjusted free cash flow.
The company will discuss these results on an earnings call at 10:00 a.m. Eastern Time on Thursday, October 30, 2025. The furnished information is not deemed filed under the Exchange Act. The filing also details how the leverage ratio is calculated under the credit agreement and outlines the role of Adjusted EBITDA in covenant compliance and liquidity assessment, along with cautionary forward‑looking statements.
Encompass Health Corporation reported a change on its board of directors. On September 17, 2025, director Patricia Maryland informed the company that she is retiring from the board for health reasons, effective immediately. The filing notes the board’s appreciation for her insights and contributions, as expressed by chairman Greg Carmichael.
Encompass Health Corp provided forward-looking non-GAAP guidance in an Item 7.01 disclosure, projecting net operating revenue of $5,880 million to $5,980 million, Adjusted EBITDA of $1,220 million to $1,250 million, and adjusted earnings per share from continuing operations of $5.12 to $5.34. The company states it does not provide comprehensive GAAP guidance because certain items cannot be reliably predicted, but it estimates 2025 interest expense and amortization of debt discounts and fees of approximately $125 million and amortization of debt-related items of approximately $10 million. The disclosure is furnished under Regulation FD and is not deemed "filed" for Section 18 purposes.
Encompass Health Corporation (NYSE: EHC) has published a new Investor Reference Book on June 25, 2025, providing comprehensive insights into the company's operations, strategy, and financial metrics. The document includes details about the company's business outlook, growth strategy, and operational initiatives.
The filing provides important context around non-GAAP financial measures, specifically:
- Leverage Ratio: Defined as consolidated total debt to Adjusted EBITDA for trailing four quarters
- Adjusted EBITDA: A key liquidity measure used in credit agreement covenants
- Adjusted Free Cash Flow: Used to assess debt reduction capacity and development potential
The company emphasizes that noncompliance with financial covenants could trigger immediate debt repayment requirements. The filing includes forward-looking statements addressing potential risks such as infectious disease outbreaks, regulatory changes, staffing challenges, and cybersecurity threats that could impact future performance.